Подписаться
Anthony Letai
Anthony Letai
Professor of Medicine, Dana-Farber Cancer Institute
Подтвержден адрес электронной почты в домене dfci.harvard.edu - Главная страница
Название
Процитировано
Процитировано
Год
The landscape of somatic copy-number alteration across human cancers
R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ...
Nature 463 (7283), 899-905, 2010
41712010
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf, SW Elmore, AR Shoemaker, RC Armstrong, DJ Augeri, ...
Nature 435 (7042), 677-681, 2005
40342005
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai, MC Bassik, LD Walensky, MD Sorcinelli, S Weiler, SJ Korsmeyer
Cancer cell 2 (3), 183-192, 2002
21202002
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ...
New England Journal of Medicine 383 (7), 617-629, 2020
17382020
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ...
Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019
15932019
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
M Certo, VDG Moore, M Nishino, G Wei, S Korsmeyer, SA Armstrong, ...
Cancer cell 9 (5), 351-365, 2006
15192006
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
R Singh, A Letai, K Sarosiek
Nature reviews Molecular cell biology 20 (3), 175-193, 2019
15062019
Control of mitochondrial apoptosis by the Bcl-2 family
JK Brunelle, A Letai
Journal of cell science 122 (4), 437-441, 2009
11232009
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
JT Opferman, A Letai, C Beard, MD Sorcinelli, CC Ong, SJ Korsmeyer
Nature 426 (6967), 671-676, 2003
10002003
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
M Konopleva, DA Pollyea, J Potluri, B Chyla, L Hogdal, T Busman, ...
Cancer discovery 6 (10), 1106-1117, 2016
9992016
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ...
Cancer cell 8 (5), 407-419, 2005
8402005
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
VDG Moore, JR Brown, M Certo, TM Love, CD Novina, A Letai
The Journal of clinical investigation 117 (1), 112-121, 2007
7392007
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia
R Pan, LJ Hogdal, JM Benito, D Bucci, L Han, G Borthakur, J Cortes, ...
Cancer discovery 4 (3), 362-375, 2014
7072014
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
AG Letai
Nature Reviews Cancer 8 (2), 121-132, 2008
7052008
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label …
CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ...
The lancet oncology 19 (2), 216-228, 2018
6852018
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy
TN Chonghaile, KA Sarosiek, TT Vo, JA Ryan, A Tammareddi, ...
Science 334 (6059), 1129-1133, 2011
6282011
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents
J Deng, N Carlson, K Takeyama, P Dal Cin, M Shipp, A Letai
Cancer cell 12 (2), 171-185, 2007
5942007
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ...
Nature 529 (7586), 413-417, 2016
5922016
Precision medicine for cancer with next-generation functional diagnostics
AA Friedman, A Letai, DE Fisher, KT Flaherty
Nature Reviews Cancer 15 (12), 747-756, 2015
5822015
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
JL Guerriero, A Sotayo, HE Ponichtera, JA Castrillon, AL Pourzia, ...
Nature 543 (7645), 428-432, 2017
4812017
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20